전역
중국
Sydney - Novotech, a leading biotech specialist CRO in the Asia-Pacific region, is sponsoring the ChinaTrials13 conference and will have teams from Novotech’s China offices attending to support biotechs planning clinical trials in China and the Asia-Pacific region (11-21, November 2021).
The conference brings together China biotechs as well as regional and international firms looking to expedite quality trials.
Of particular focus is oncology research. According to GlobalData, China has the highest incidence of cancer in the world, accounting for 24% of newly diagnosed cases and 30% of cancer-related deaths worldwide in 2020.
Meet the Novotech team at Booth: #11&12
Presentations by Novotech
Workshop: Navigating the Future of Cell Therapies Development: Unlocking the Full Potential
10th November, 9am – 12pm
Topics include:
- CAR-T Therapy: Key considerations during clinical development
- Execution and quality management for cell therapy clinical development
- Statistical considerations in CAR-T therapy clinical trials
Key Novotech experts along with industry leaders will present, then open up for discussions around key issues.
Some of the topics covered at the conference include:
- The Next Phase of Chinese Innovative Biotech Drug Development
- China+US Development: Should You File Your IND in the US Before/After or Simultaneously Alongside Your China IND?
- China CMO Roundtable: What's On the Minds of China's Top CMO's?
- Decentralized Clinical Studies: How COVID-19 Changed Clinical Development & Lessons Learned
- Regulatory Insights: Taking Advantage of Fast Track Channels
- MNC Perspectives: China's New Role in Global Development
- Global Drug Development 2.0: Borderless Innovation
- Cell & Gene Therapy Drug Development in China: What's Next?
- Experience Sharing: China Biotech + MNC Pharma Drug Development Partnerships
- Digital Technology to Support Remote Inspection to Accelerate Clinical Research: PI, Site and Sponsor Perspectives
- Choosing the Right Clinical Development Strategy to Optimize Regulatory Approval Pathway
- Win From the Start: Early Clinical Research Strategies for Innovative Drugs
- Strategy & Planning of Innovative Drugs in MRCT
- How to Design Trials to Better Serve the Needs of Clinical & Needs of Patients
- Strategies for Moving Quickly from Phase I to Phase II
- Seamless Global Development from Phase I to III: A Tale of COVID-19 Antibody Cocktail Therapy
- Real World Data: The Road to Bringing Innovative Therapies to Patients Faster?
Media contact
데이빗 제임스 (David James)
노보텍은 글로벌 실행 능력을 갖춘 아시아 태평양 중심의 선도적인 바이오텍 CRO 기업으로 국제적으로 인정받고 있습니다.
노보텍은 연구소, 임상1상 시험 기관, 약물 개발 컨설팅 서비스(DDC, Drug Development Consulting) 그리고 FDA 규제 전문성을 갖춘 임상 CRO 기업으로 1상에서부터 4상까지의 임상시험과 생물학적 동등성 시험을 포함하여 5,000건 이상의 임상 프로젝트에 참여한 경험이 있습니다. 노보텍은 아시아 태평양, 미국, 유럽에서 임상시험을 수행하고자 하는 바이오텍 고객들에게 서비스를 제공할 수 있습니다. 노보텍은 전 세계적으로 3,000명 이상의 직원과 34개의 사무실을 보유하고 있습니다.
보다 자세한 내용은 https://novotech-cro.com/contact를 통해 확인하실 수 있습니다.